ALXN Alexion Pharmaceuticals Inc

By Ian Walker

AstraZeneca PLC on Wednesday priced a six-part $7 billion global bond offering, which will be used to pay part of its acquisition of Alexion Pharmaceuticals Inc.

The pharmaceutical giant, which agreed to buy Boston-based Alexion Pharmaceuticals last December for $39 billion in cash and stock, said it will also use any money raised to repay or refinance part of Alexion's debt, as well as for general corporate purposes.

The notes, which carry coupons of between 0.3% and 3.0%, mature between May 26, 2023 and May 28, 2051.

On Tuesday the U.K. Competition and Markets Authority said that it was considering whether AstraZeneca's acquisition of Alexion would lessen competition within the U.K., and invited comments from interested parties ahead of a final decision.

The regulator said interested parties have until June 3 to offer their comments. It has set a deadline of July 21 for a Phase 1 decision on the deal.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

May 26, 2021 02:30 ET (06:30 GMT)

Alexion Pharmaceuticals (NASDAQ:ALXN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Alexion Pharmaceuticals (NASDAQ:ALXN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024